Although KRAS G12-mutated CRCs are generally associated with poor prognosis, a considerable percentage of KRAS WT CRCs showed low DFS and some KRAS G12 mutated CRCs showed high DFS regardless of their tumor stage (Fig. 1A). This evidence concerns the gene KRAS and neoplasm.